Resources

When early type 2 diabetes is detected by screening, intensive management doesn’t seem to cut the risk of certain complications later on, a Danish study indicates.…

ACOG agrees on the approach to screening and diagnosis for GDM in the continued absence of an international consensus on whether the benefits of some screening approaches outweigh the costs.…

In two recent trials, the investigational drug GFT505 improved lipid and glucose disorders in abdominally obese patients with combined dyslipidemias or prediabetes.…

When it comes to self-monitoring of blood glucose, it’s not the quantity that matters, it’s the quality of the testing….

A study found that participants face a 7% increase in mortality risk for every two years of being obese, while every 10 years of obesity more than doubles the risk of all-cause mortality.…

Combining nuts, plant-based foods with low-fat diet produces biggest drops, researchers say.…

According to the results of a new study, a significant number of children and young adults with diabetes may not be getting the routine tests recommended for managing the disease.…

According to the latest findings from a landmark San Antonio-led study, diabetes seems to be deadlier for Mexican Americans than for Anglos, and much deadlier for diabetes patients living in Mexico.…

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Ms. CP self-referred to a diabetes educator for advice. “I have had type 2 diabetes for 8 years and I take metformin and Diamicron (gliclazide) every day. I go to the …

See more GLP-1 Agonist Resources. This week we wrap-up our four part series on GLP-1 Agonists. Topics covered this week include: "Treatment with Exenatide does not impair the counterregulatory glucagon response," "Incretin-related Anti-diabetes Drugs and effects on plasma glucagon," and "A new extra-islet target for GLP-1: The Heart"…. Link to …